John Newman
Stock Analyst at Canaccord Genuity
(1.47)
# 3,286
Out of 4,870 analysts
81
Total ratings
42.25%
Success rate
-12%
Average return
Main Sectors:
Stocks Rated by John Newman
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| REGN Regeneron Pharmaceuticals | Maintains: Buy | $1,152 → $850 | $511.92 | +66.04% | 16 | Apr 22, 2025 | |
| ALLO Allogene Therapeutics | Maintains: Buy | $14 | $1.22 | +1,047.54% | 3 | Mar 14, 2025 | |
| BNTX BioNTech SE | Maintains: Buy | $171 | $103.01 | +66.43% | 8 | Mar 11, 2025 | |
| ATRA Atara Biotherapeutics | Maintains: Buy | $17 | $7.88 | +115.74% | 5 | Mar 11, 2025 | |
| MRKR Marker Therapeutics | Initiates: Buy | $8 | $1.42 | +463.38% | 1 | Mar 5, 2025 | |
| CADL Candel Therapeutics | Maintains: Buy | $20 → $25 | $4.67 | +435.33% | 2 | Feb 26, 2025 | |
| MCRB Seres Therapeutics | Maintains: Buy | $200 | $7.42 | +2,595.42% | 9 | Nov 14, 2024 | |
| DCTH Delcath Systems | Maintains: Buy | $21 | $13.26 | +58.37% | 1 | Oct 18, 2024 | |
| ACLX Arcellx | Maintains: Buy | $85 → $115 | $63.64 | +80.70% | 8 | Oct 17, 2024 | |
| ACET Adicet Bio | Maintains: Buy | $19 → $8 | $0.63 | +1,160.24% | 6 | Sep 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $67 | $52.76 | +26.99% | 2 | Jul 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $38 → $43 | $9.83 | +337.44% | 1 | Jul 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $5 | $0.64 | +684.93% | 2 | Jun 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $52 → $44 | $33.33 | +32.01% | 9 | Feb 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $210 → $220 | $9.29 | +2,268.14% | 3 | Jun 13, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $30 → $38 | $15.09 | +151.82% | 2 | Oct 17, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $12 → $27 | $3.09 | +775.20% | 2 | Sep 13, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Speculative Buy | n/a | $7.83 | - | 1 | Sep 13, 2017 |
Regeneron Pharmaceuticals
Apr 22, 2025
Maintains: Buy
Price Target: $1,152 → $850
Current: $511.92
Upside: +66.04%
Allogene Therapeutics
Mar 14, 2025
Maintains: Buy
Price Target: $14
Current: $1.22
Upside: +1,047.54%
BioNTech SE
Mar 11, 2025
Maintains: Buy
Price Target: $171
Current: $103.01
Upside: +66.43%
Atara Biotherapeutics
Mar 11, 2025
Maintains: Buy
Price Target: $17
Current: $7.88
Upside: +115.74%
Marker Therapeutics
Mar 5, 2025
Initiates: Buy
Price Target: $8
Current: $1.42
Upside: +463.38%
Candel Therapeutics
Feb 26, 2025
Maintains: Buy
Price Target: $20 → $25
Current: $4.67
Upside: +435.33%
Seres Therapeutics
Nov 14, 2024
Maintains: Buy
Price Target: $200
Current: $7.42
Upside: +2,595.42%
Delcath Systems
Oct 18, 2024
Maintains: Buy
Price Target: $21
Current: $13.26
Upside: +58.37%
Arcellx
Oct 17, 2024
Maintains: Buy
Price Target: $85 → $115
Current: $63.64
Upside: +80.70%
Adicet Bio
Sep 11, 2024
Maintains: Buy
Price Target: $19 → $8
Current: $0.63
Upside: +1,160.24%
Jul 25, 2024
Maintains: Buy
Price Target: $67
Current: $52.76
Upside: +26.99%
Jul 3, 2024
Maintains: Buy
Price Target: $38 → $43
Current: $9.83
Upside: +337.44%
Jun 23, 2023
Reiterates: Buy
Price Target: $5
Current: $0.64
Upside: +684.93%
Feb 16, 2022
Maintains: Buy
Price Target: $52 → $44
Current: $33.33
Upside: +32.01%
Jun 13, 2018
Maintains: Buy
Price Target: $210 → $220
Current: $9.29
Upside: +2,268.14%
Oct 17, 2017
Maintains: Buy
Price Target: $30 → $38
Current: $15.09
Upside: +151.82%
Sep 13, 2017
Maintains: Buy
Price Target: $12 → $27
Current: $3.09
Upside: +775.20%
Sep 13, 2017
Downgrades: Speculative Buy
Price Target: n/a
Current: $7.83
Upside: -